Mirati Therapeutics Company Profile (NASDAQ:MRTX)

About Mirati Therapeutics (NASDAQ:MRTX)

Mirati Therapeutics logo

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:MRTX
  • CUSIP: N/A
  • Web: www.mirati.com
  • Market Cap: $81.05 million
  • Outstanding Shares: 24,939,000
Average Prices:
  • 50 Day Moving Avg: $4.03
  • 200 Day Moving Avg: $5.10
  • 52 Week Range: $3.10 - $19.25
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.97 per share
  • Price / Book: 0.82
  • EBIDTA: ($77,080,000.00)
  • Return on Equity: -89.06%
  • Return on Assets: -78.73%
  • Current Ratio: 5.53%
  • Quick Ratio: 5.53%
  • Average Volume: 137,211 shs.
  • Beta: 1.15
  • Short Ratio: 7.02

Frequently Asked Questions for Mirati Therapeutics (NASDAQ:MRTX)

What is Mirati Therapeutics' stock symbol?

Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX."

How were Mirati Therapeutics' earnings last quarter?

Mirati Therapeutics, Inc. (NASDAQ:MRTX) released its quarterly earnings results on Thursday, March, 9th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.97) by $0.02. View Mirati Therapeutics' Earnings History.

Where is Mirati Therapeutics' stock going? Where will Mirati Therapeutics' stock price be in 2017?

8 analysts have issued 12-month price objectives for Mirati Therapeutics' shares. Their predictions range from $5.50 to $27.00. On average, they anticipate Mirati Therapeutics' stock price to reach $13.07 in the next year. View Analyst Ratings for Mirati Therapeutics.

What are analysts saying about Mirati Therapeutics stock?

Here are some recent quotes from research analysts about Mirati Therapeutics stock:

  • 1. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (5/4/2017)
  • 2. Jefferies Group LLC analysts commented, "MRTX reported clinical updates on lead programs, glesatinib and sitravatinib. ID’ing glesatinib’s optimal patient pop (MET amp) as well as better safety w/ lower discontinuation rate on new formulation could start to pay off as more pts enter ph.II, which could help enable them to show whether activity is differentiated. Sitravatinib data remains early." (1/9/2017)

Who are some of Mirati Therapeutics' key competitors?

Who owns Mirati Therapeutics stock?

Mirati Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include Aviva Holdings Ltd. (11.55%), Broadfin Capital LLC (8.38%), Boxer Capital LLC (4.16%), Vanguard Group Inc. (2.75%), Sabby Management LLC (1.00%) and Renaissance Technologies LLC (0.66%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum, Ltd Braslyn and Mark J Gergen. View Institutional Ownership Trends for Mirati Therapeutics.

Who sold Mirati Therapeutics stock? Who is selling Mirati Therapeutics stock?

Mirati Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Morgan Stanley, TIAA CREF Investment Management LLC, UBS Group AG and Alliancebernstein L.P.. View Insider Buying and Selling for Mirati Therapeutics.

Who bought Mirati Therapeutics stock? Who is buying Mirati Therapeutics stock?

Mirati Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including Broadfin Capital LLC, Aviva Holdings Ltd., Boxer Capital LLC, Renaissance Technologies LLC, Vanguard Group Inc., Sabby Management LLC, Royce & Associates LP and Dimensional Fund Advisors LP. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Bros Advisors Lp Baker, Charles M Baum and Ltd Braslyn. View Insider Buying and Selling for Mirati Therapeutics.

How do I buy Mirati Therapeutics stock?

Shares of Mirati Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mirati Therapeutics' stock price today?

One share of Mirati Therapeutics stock can currently be purchased for approximately $3.25.

MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)
Community Ranking:  3.2 out of 5 (  )
Outperform Votes:  138 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  219
MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Mirati Therapeutics (NASDAQ:MRTX) (?)
Ratings Breakdown: 4 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $13.07 (302.20% upside)

Analysts' Ratings History for Mirati Therapeutics (NASDAQ:MRTX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/12/2017Jefferies Group LLCReiterated RatingHold$5.50HighView Rating Details
3/11/2017HC WainwrightSet Price TargetBuy$12.00 -> $10.00N/AView Rating Details
11/18/2016Avondale PartnersDowngradeOutperform -> Market PerformN/AView Rating Details
11/11/2016Leerink SwannReiterated RatingHold$7.00N/AView Rating Details
11/4/2016WedbushReiterated RatingOutperform$12.00N/AView Rating Details
8/18/2016Piper Jaffray CompaniesSet Price TargetHold$7.00N/AView Rating Details
6/6/2016Barclays PLCLower Price TargetOverweight$41.00 -> $27.00N/AView Rating Details
6/6/2016Citigroup IncLower Price TargetBuy$30.00 -> $23.00N/AView Rating Details
3/1/2016SunTrust Banks, Inc.Initiated CoverageBuy$32.00N/AView Rating Details
6/1/2015Brean CapitalDowngradeBuy -> HoldN/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Mirati Therapeutics (NASDAQ:MRTX)
Earnings by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Earnings History by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/9/2017Q4 2016($0.97)($0.99)ViewN/AView Earnings Details
8/4/2016Q2($1.15)($1.11)ViewN/AView Earnings Details
5/5/2016Q1($0.99)($1.13)ViewN/AView Earnings Details
3/9/2016Q4($1.03)($0.96)ViewN/AView Earnings Details
11/6/2015Q3 2015($0.88)($1.11)ViewN/AView Earnings Details
8/6/2015Q2 2015($0.74)($0.95)ViewN/AView Earnings Details
5/6/2015Q1 2015($0.71)($0.77)ViewN/AView Earnings Details
3/11/2015Q414($1.00)($0.77)ViewN/AView Earnings Details
11/10/2014Q314($0.77)($0.72)ViewN/AView Earnings Details
8/8/2014Q214($0.69)($0.82)ViewN/AView Earnings Details
3/18/2014Q413($0.66)($0.97)ViewN/AView Earnings Details
11/12/2013Q313($0.78)($2.95)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Mirati Therapeutics (NASDAQ:MRTX)
2017 EPS Consensus Estimate: ($3.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($1.08)($0.80)($0.91)
Q2 20173($1.10)($0.74)($0.89)
Q3 20173($1.12)($0.76)($0.91)
Q4 20173($1.16)($0.75)($0.92)
(Data provided by Zacks Investment Research)


Dividend History for Mirati Therapeutics (NASDAQ:MRTX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Mirati Therapeutics (NASDAQ:MRTX)
Insider Ownership Percentage: 4.80%
Institutional Ownership Percentage: 50.41%
Insider Trades by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Insider Trades by Quarter for Mirati Therapeutics (NASDAQ:MRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/26/2017Ltd. BraslynMajor ShareholderBuy48,169$5.45$262,521.05View SEC Filing  
1/25/2017Ltd. BraslynMajor ShareholderBuy30,600$5.42$165,852.00View SEC Filing  
1/24/2017Ltd. BraslynMajor ShareholderBuy27,682$5.32$147,268.24View SEC Filing  
1/23/2017Ltd. BraslynMajor ShareholderBuy19,251$5.27$101,452.77View SEC Filing  
1/20/2017Ltd. BraslynMajor ShareholderBuy61,158$5.46$333,922.68View SEC Filing  
1/17/2017Ltd. BraslynMajor ShareholderBuy119,887$5.50$659,378.50View SEC Filing  
1/6/2017Boxer Capital, LlcMajor ShareholderBuy286,163$5.60$1,602,512.80View SEC Filing  
6/14/2016Charles M BaumCEOBuy20,000$7.05$141,000.00View SEC Filing  
6/9/2016Bros. Advisors Lp BakerMajor ShareholderSell999,358$9.41$9,403,958.78View SEC Filing  
6/7/2016Ltd. BraslynMajor ShareholderBuy376,902$9.96$3,753,943.92View SEC Filing  
5/6/2016Ltd. BraslynMajor ShareholderBuy65,782$18.21$1,197,890.22View SEC Filing  
3/28/2016Ltd. BraslynMajor ShareholderBuy20,848$19.36$403,617.28View SEC Filing  
3/18/2016Ltd. BraslynMajor ShareholderBuy1,166$19.34$22,550.44View SEC Filing  
1/15/2016Mark J. GergenCOOSell10,000$25.92$259,200.00View SEC Filing  
9/16/2015Bros. Advisors Lp BakerMajor ShareholderBuy150,000$45.00$6,750,000.00View SEC Filing  
5/26/2015Jamie ChristensenSVPSell4,750$28.07$133,332.50View SEC Filing  
3/5/2015Jamie ChristensenSVPSell6,000$25.41$152,460.00View SEC Filing  
2/19/2015Jamie ChristensenSVPSell4,750$22.84$108,490.00View SEC Filing  
2/3/2015Orbimed Advisors LlcMajor ShareholderBuy100,000$20.00$2,000,000.00View SEC Filing  
1/29/2015Bros. Advisors Lp BakerMajor ShareholderBuy425,000$20.00$8,500,000.00View SEC Filing  
7/1/2014Orbimed Advisors LlcMajor ShareholderSell107,332$21.66$2,324,811.12View SEC Filing  
11/26/2013Charles M BaumCEOBuy5,000$16.96$84,800.00View SEC Filing  
10/29/2013Orbimed Advisors LlcMajor ShareholderBuy125,000$17.50$2,187,500.00View SEC Filing  
10/24/2013Tang Capital Partners LpMajor ShareholderBuy57,143$17.50$1,000,002.50View SEC Filing  
9/20/2013Tang Capital Partners LpMajor ShareholderSell36,898$16.34$602,913.32View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Mirati Therapeutics (NASDAQ:MRTX)
Latest Headlines for Mirati Therapeutics (NASDAQ:MRTX)
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - May 19 at 9:01 AM
americanbankingnews.com logoQ2 2017 Earnings Estimate for Mirati Therapeutics, Inc. Issued By Jefferies Group (MRTX)
www.americanbankingnews.com - May 10 at 8:14 AM
americanbankingnews.com logoZacks: Brokerages Expect Mirati Therapeutics, Inc. (MRTX) to Announce -$0.77 EPS
www.americanbankingnews.com - May 9 at 8:10 AM
americanbankingnews.com logoZacks Investment Research Lowers Mirati Therapeutics, Inc. (MRTX) to Hold
www.americanbankingnews.com - May 7 at 8:55 PM
marketbeat.com logoMirati reports 1Q loss
marketbeat.com - May 4 at 6:57 PM
finance.yahoo.com logoMirati Therapeutics Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 4 at 6:45 PM
americanbankingnews.com logoPositive Media Coverage Extremely Likely to Affect Mirati Therapeutics (MRTX) Stock Price
www.americanbankingnews.com - May 2 at 8:52 AM
americanbankingnews.com logoMirati Therapeutics (MRTX) Given Daily News Impact Rating of 0.37
www.americanbankingnews.com - April 28 at 6:18 PM
americanbankingnews.com logoMirati Therapeutics (MRTX) Getting Somewhat Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 25 at 9:22 PM
americanbankingnews.com logoMirati Therapeutics (MRTX) Earning Somewhat Negative News Coverage, Study Finds
www.americanbankingnews.com - April 22 at 8:06 AM
americanbankingnews.com logoMirati Therapeutics (MRTX) Earning Positive News Coverage, Study Finds
www.americanbankingnews.com - April 18 at 2:00 PM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Given Hold Rating at Jefferies Group LLC
www.americanbankingnews.com - April 18 at 8:59 AM
americanbankingnews.com logoPositive Press Coverage Extremely Likely to Impact Mirati Therapeutics (MRTX) Share Price
www.americanbankingnews.com - April 13 at 8:59 AM
americanbankingnews.com logoMirati Therapeutics' (MRTX) Hold Rating Reaffirmed at Jefferies Group LLC
www.americanbankingnews.com - April 12 at 3:14 PM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Sees Significant Increase in Short Interest
www.americanbankingnews.com - April 8 at 9:30 AM
americanbankingnews.com logoMirati Therapeutics, Inc. (MRTX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 28 at 12:16 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
biz.yahoo.com - March 27 at 6:10 PM
finance.yahoo.com logoMIRATI THERAPEUTICS, INC. Financials
finance.yahoo.com - March 15 at 6:51 PM
finance.yahoo.com logoMirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016
finance.yahoo.com - March 9 at 6:27 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 6:27 PM
finance.yahoo.com logoMirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference
finance.yahoo.com - February 13 at 7:48 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
biz.yahoo.com - February 8 at 7:32 PM
finance.yahoo.com logoMirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter's Option to Purchase Additional Shares
finance.yahoo.com - January 11 at 7:15 PM
investopedia.com logoMirati Launches $65M Public Stock Offering (MRTX)
www.investopedia.com - January 9 at 7:21 PM
investopedia.com logoMirati Therapeutics Sets $65M Public Offering
www.investopedia.com - January 9 at 7:21 PM
nasdaq.com logoMRTX Prices Offering At $5.60/Share
www.nasdaq.com - January 9 at 4:26 AM
us.rd.yahoo.com logo7:31 am Mirati Therapeutics prices an underwritten public offering of 4,350,176 shares of its common stock at a price to the public of $5.60/share
us.rd.yahoo.com - January 6 at 7:21 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - January 6 at 7:21 PM
streetinsider.com logoMirati Therapeutics (MRTX) Offers Data from on Glesatinib and Sitravatinib Clinical Trials - StreetInsider.com
www.streetinsider.com - January 6 at 1:06 AM
streetinsider.com logoMirati Therapeutics (MRTX) Plans Offering of Common Stock
www.streetinsider.com - January 5 at 8:05 PM
finance.yahoo.com logo4:02 pm Mirati Therapeutics announces data from 2 ongoing clinical programs including the Phase 1b & Phase 2 trials of glesatinib; co intends to offer & sell shares of its common stock
finance.yahoo.com - January 5 at 8:05 PM
biz.yahoo.com logoMIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events
biz.yahoo.com - January 5 at 8:05 PM
finance.yahoo.com logoHow Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry
finance.yahoo.com - December 9 at 6:41 PM



Mirati Therapeutics (MRTX) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff